Published in Arthritis Rheum on October 01, 1991
Helicobacter pylori seropositivity in fibromyalgia syndrome. Clin Rheumatol (2010) 1.96
Pathogenesis of human parvovirus B19 in rheumatic disease. Ann Rheum Dis (2000) 1.82
Fibromyalgia syndrome: etiology, pathogenesis, diagnosis, and treatment. Pain Res Treat (2012) 1.15
Seroprevalence of parvovirus B19 in fibromyalgia syndrome. Clin Rheumatol (2008) 0.86
Fibromyalgia syndrome in patients with hepatitis C infection. Rheumatol Int (2003) 0.85
Human Parvoviruses. Clin Microbiol Rev (2017) 0.84
The prevalence of fibromyalgia among patients with hepatitis B virus infection. Int J Clin Exp Med (2013) 0.75
Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial. Arch Dermatol (1992) 2.33
Use of gelatin/plasma coated flasks for isolating human peripheral blood monocytes. J Immunol Methods (1983) 2.12
Cytokine networks in the regulation of inflammation and fibrosis in the lung. Chest (1990) 1.86
Synergistic stimulation of fibroblast prostaglandin production by recombinant interleukin 1 and tumor necrosis factor. J Immunol (1987) 1.73
Selective inhibition of human diploid fibroblast collagen synthesis by interferons. J Clin Invest (1984) 1.70
T cell development in B cell-deficient mice. IV. The role of B cells as antigen-presenting cells in vivo. J Immunol (1986) 1.62
Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis (2010) 1.58
Molecular detection of bacterial DNA in venereal-associated arthritis. Arthritis Rheum (1996) 1.55
The cytotoxic effector cells in preparations of adherent mononuclear cells from human peripheral blood. J Immunol (1984) 1.50
Induction of an invasive phenotype by human parvovirus B19 in normal human synovial fibroblasts. Arthritis Rheum (2001) 1.47
Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis (2011) 1.46
Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis (2006) 1.42
Human parvovirus B19 infection among hospital staff members after contact with infected patients. N Engl J Med (1989) 1.40
Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial. Ann Rheum Dis (2005) 1.32
Transcriptional control of human diploid fibroblast collagen synthesis by gamma-interferon. Biochem Biophys Res Commun (1984) 1.27
Inhibition of excessive scleroderma fibroblast collagen production by recombinant gamma-interferon. Association with a coordinate decrease in types I and III procollagen messenger RNA levels. Arthritis Rheum (1986) 1.19
Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48. Ann Rheum Dis (2011) 1.18
Completeness of prescription recording in outpatient medical records from a health maintenance organization. J Clin Epidemiol (1994) 1.16
Parvovirus B19-specific DNA in bone marrow from B19 arthropathy patients: evidence for B19 virus persistence. J Infect Dis (1993) 1.14
Multiple glycosphingolipids determine the tissue tropism of parvovirus B19. J Infect Dis (1995) 1.13
Cytokine regulation of human lung fibroblast hyaluronan (hyaluronic acid) production. Evidence for cytokine-regulated hyaluronan (hyaluronic acid) degradation and human lung fibroblast-derived hyaluronidase. J Clin Invest (1992) 1.11
Parvovirus B19 as a possible causative agent of fulminant liver failure and associated aplastic anemia. Hepatology (1995) 1.08
Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Ann Rheum Dis (2010) 1.05
Regulation of human lung fibroblast glycosaminoglycan production by recombinant interferons, tumor necrosis factor, and lymphotoxin. J Clin Invest (1988) 1.04
Human parvovirus B19 infection in acute fulminant liver failure. Arch Virol (1999) 1.01
Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate. Ann Rheum Dis (2008) 1.00
Subcutaneous pancreatic fat necrosis associated with acute arthritis. J Rheumatol (1992) 0.99
Hepatitis E virus infection prevalence among selected populations in Iowa. J Clin Virol (1999) 0.98
Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis. Clin Exp Rheumatol (2010) 0.98
Recombinant gamma, alpha, and beta interferon regulation of human lung fibroblast proliferation. Am Rev Respir Dis (1987) 0.96
T cell development in B cell deficient mice. III. Restriction specificity of suppressor T cell factor(s) produced in mice treated chronically with rabbit anti-mouse mu chain antibody. J Mol Cell Immunol (1985) 0.96
A controlled investigation of current and premorbid personality: characteristics of Parkinson's disease patients. Mov Disord (1995) 0.93
Regulation of human lung fibroblast collagen production by recombinant interleukin-1, tumor necrosis factor, and interferon-gamma. Ann N Y Acad Sci (1990) 0.93
Shingles, allergies, family medical history, oral contraceptives, and other potential risk factors for systemic lupus erythematosus. Am J Epidemiol (1994) 0.93
Breast silicone implants and risk of systemic lupus erythematosus. J Clin Epidemiol (1994) 0.92
Molecular diagnosis of Ureaplasma urealyticum septic arthritis in a patient with hypogammaglobulinemia. Arthritis Rheum (1992) 0.91
Infection due to parvovirus B19 in patients infected with human immunodeficiency virus. Clin Infect Dis (1995) 0.91
Pulmonary alveolar hemorrhage in systemic lupus erythematosus. Semin Arthritis Rheum (1993) 0.89
Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens. J Eur Acad Dermatol Venereol (2011) 0.88
Antiphospholipid antibody syndrome with right atrial thrombosis mimicking an atrial myxoma. Am J Med (1989) 0.88
Cerebral blood flow variations in CNS lupus. Neurology (1990) 0.87
Human alveolar macrophage and blood monocyte inhibition of fibroblast proliferation. Evidence for synergy between interleukin-1 and tumor necrosis factor. Am Rev Respir Dis (1988) 0.86
Acetylation phenotypes and environmental chemical exposure of people with idiopathic systemic lupus erythematosus. Arthritis Rheum (1993) 0.86
The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy. Ann Rheum Dis (2007) 0.85
Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial. J Eur Acad Dermatol Venereol (2010) 0.84
Gonococcal septic arthritis of the hip. J Rheumatol (1991) 0.84
Human parvovirus B19 infection and hepatitis. Lancet (1996) 0.84
Transient blood plasmacytosis in parvovirus B19 infection: a report of two cases. Ann Hematol (1996) 0.84
Parvovirus B19 infection in patients receiving cancer chemotherapy: the expanding spectrum of disease. Am J Pediatr Hematol Oncol (1989) 0.83
Molecular diagnosis of Borrelia burgdorferi infection (Lyme disease). DNA Cell Biol (1992) 0.83
Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy. Ann Rheum Dis (2008) 0.82
The role of xenoantigen in the human autologous mixed lymphocyte reaction: ability to respond in the absence of exposure to xenoantigen depends on the method of T-cell preparation. Clin Immunol Immunopathol (1985) 0.81
Differential prostaglandin production by unfractionated and density-fractionated human monocytes and alveolar macrophages. J Leukoc Biol (1987) 0.81
Suppressor T-cell factor(s) display an altered pattern of Igh (immunoglobulin heavy chain locus) genetic restriction when developed in an Igh-congeneic host. Proc Natl Acad Sci U S A (1985) 0.81
Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept. Br J Dermatol (2009) 0.81
The role of fatty acid metabolites in the differentiation of the human monocyte-like cell line U937. J Leukoc Biol (1988) 0.80
Comment on the 1990 American College of rheumatology criteria for fibromyalgia. Arthritis Rheum (1990) 0.80
Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial. Ann Rheum Dis (2007) 0.80
Treatment of autoimmune disease with extracorporeal photochemotherapy: progressive systemic sclerosis. Yale J Biol Med (1990) 0.79
Black tongue. Arch Dermatol (2001) 0.79
Transplantation of systemic sclerosis (SSc) skin grafts into severe combined immunodeficient mice: increased presence of SSc leukocytes in SSc skin grafts and autoantibody production following autologous leukocyte transfer. Pathobiology (1996) 0.79
Scleromyxedema with myopathy and hyperthyroidism. J Rheumatol (1996) 0.79
Relapse of systemic lupus erythematosus in a patient receiving cyclosporine A. J Rheumatol (1988) 0.79
Jaccoud arthropathy and acroosteolysis in KID syndrome. J Rheumatol (1989) 0.78
Bilateral periorbital edema in systemic lupus erythematosus. J Rheumatol (1993) 0.78
Intrauterine transfusion treatment of nonimmune hydrops fetalis secondary to human parvovirus B19 infection. Am J Obstet Gynecol (1991) 0.78
Psoriatic and seronegative inflammatory arthropathy associated with a traumatic onset: 4 cases and a review of the literature. J Rheumatol (1997) 0.78
Hypertrophic osteoarthropathy as indication of aortic graft infection and aortoenteric fistula. Arch Surg (1982) 0.78
Suppression of antigen-specific interleukin 2 production in the MRL/MpJ-lpr/lpr mouse. J Immunol (1986) 0.77
Regulation of hapten-specific T-cell response. II. Functional analysis of helper T cells and cytotoxic T cells in animals suppressed by azobenzenearsonate (ABA)-specific suppressor T cells. Cell Immunol (1985) 0.77
Fetal survival after human parvovirus B19 infection: spectrum of intrauterine response in a twin gestation. Am J Perinatol (1992) 0.77
Parvovirus B19 infection causing pure red cell aplasia in a recipient of pediatric donor kidneys. Transplantation (1993) 0.76
Parvovirus b19 infection associated with acute hepatitis, arthralgias, and rash. J Clin Rheumatol (1996) 0.76
Absence of parvovirus B19 infection in chronic fatigue syndrome. Arthritis Rheum (1995) 0.76
Diagnosis of fetal infection in the patient with an ultrasonographically detected abnormality but a negative clinical history. Am J Obstet Gynecol (1993) 0.76
Idiopathic regional osteoporosis: a clinical spectrum. J Rheumatol (1985) 0.75
Knee contractures as the presenting manifestation of scleroderma. Ann Rheum Dis (1992) 0.75
Aseptic meningitis caused by parvovirus B19. Clin Infect Dis (1995) 0.75
Molecular diagnosis of Borrelia burgdorferi infection (Lyme disease). DNA Cell Biol (1994) 0.75
Controlled study of sleep parameters in patients with fibromyalgia. J Clin Rheumatol (1995) 0.75
Photopheresis for scleroderma? Let's abandon the innuendos and get to the data. J Rheumatol (1993) 0.75
Eosinophilia-myalgia syndrome: selective cognitive impairment, longitudinal effects, and neuroimaging findings. J Neurol Neurosurg Psychiatry (1997) 0.75
Human parvovirus B19 infection in children with new onset Type 1 diabetes mellitus. Diabet Med (2005) 0.75
Established fibromyalgia syndrome and parvovirus B19 infection. J Rheumatol (1993) 0.75
Intravenous corticosteroid therapy of cervical cord compression in rheumatoid arthritis. Clin Exp Rheumatol (1992) 0.75
Systemic lupus erythematosus and the syndrome of inappropriate secretion of antidiuretic hormone. J Rheumatol (1991) 0.75
Toward rational treatment of scleroderma. Hosp Pract (Off Ed) (1993) 0.75
1,25-Dihydroxyvitamin D3 and granulomatous lesions. N Engl J Med (1985) 0.75
Human parvovirus infection. Am Fam Physician (1989) 0.75
Head and neck manifestations of eosinophilia-myalgia syndrome. Ann Otol Rhinol Laryngol (1995) 0.75
A combined pseudoreplica-immunochemical technique for research and diagnostic virology. Microsc Res Tech (1992) 0.75
Lupus erythematosus arising in striae distensae. Cutis (1983) 0.75
The role of body experience in hypnotic behavior. Int J Clin Exp Hypn (1974) 0.75